Description: Eisai Co. and its subsidiaries are engaged in the manufacture and sale of pharmaceuticals, consumer health care products, diagnostic products, chemicals and food additives, and animal health products. Co.'s products include antiallergy agent, osteoporosis treatment, gastritis/gastric ulcer medication, vitamins, food preservative, flavoring agent, and sweetening material. Co. is also engaged in the manufacture and sale of pharmaceutical production system and machines.
Home Page: www.eisai.co.jp
4-6-10, Koishikawa
Tokyo,
112-8088
Japan
Phone:
81 3 3817 3700
Officers
| Name | Title |
|---|---|
| Mr. Haruo Naito | CEO, Representative Corporate Officer & Director |
| Mr. Gary Hendler | Senior VP & President of EMEA Region |
| Dr. Lynn D. Kramer FAAN, M.D. | VP & Chief Clinical Officer |
| Ms. Yanhui Feng | Senior Vice President |
| Mr. Keisuke Naito | Representative Corporate Officer, EVP, COO & Chief Growth Officer |
| Mr. Masatomi Akana | Senior VP, Chief Government Relations Officer & Chief IR Officer |
| Shin Kato | VP, General Counsel & Chief Compliance Officer |
| Ms. Sayoko Sasaki | Vice President of Corporate Communications & Sustainability |
| Mr. Teruyuki Masaka | VP, Chief HR Officer & Corporate Officer of General Affairs Japan Subsidiaries |
| Dr. Takashi Owa Ph.D. | Senior VP & Chief Scientific Officer - Japan Medical Safety |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 32.2581 |
|---|---|
| Trailing PE: | 31.1935 |
| Price-to-Book MRQ: | 1.5183 |
| Price-to-Sales TTM: | 0.0111 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 11067 |